Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes

Journal of Immunological Methods

Volumn 308, Issue 1-2, 2006, Pages 77-89

  Chromik, Jörg ^a   Schnürer, Elke ^a   Georg Meyer, Ralf ^a   Wehler, Thomas ^a   Tüting, Thomas ^b   Wölfel, Thomas ^a   Huber, Christoph ^a   Herr, Wolfgang ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c NONE

Author keywords

Dendritic cell; Peptide; Proteasome inhibitor; T cell

Indexed keywords

ACID; CD8 ANTIGEN; EPITOPE; HLA ANTIGEN CLASS 1; PEPTIDE; PROTEASOME; PROTEASOME INHIBITOR; VACCINE;

ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CLONE CELLS; DENDRITIC CELLS; EPITOPES; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONOCYTES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

HUMAN HERPESVIRUS 4;

EID: 30844445574     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2005.09.021     Document Type: Article

References (54)

1. A.L. Ackerman, and P. Cresswell Cellular mechanisms governing cross-presentation of exogenous antigens Nat. Immunol. 5 2004 678
2. A.L. Ackerman, C. Kyritsis, R. Tampe, and P. Cresswell Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens Proc. Natl. Acad. Sci. U. S. A. 100 2003 12889
3. A.M. Benham, M. Gromme, and J. Neefjes Allelic differences in the relationship between proteasome activity and MHC class I peptide loading J. Immunol. 161 1998 83
4. M. Bogyo, J.S. McMaster, M. Gaczynska, D. Tortorella, A.L. Goldberg, and H. Ploegh Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors Proc. Natl. Acad. Sci. U. S. A. 94 1997 6629
5. C.M. Britten, R.G. Meyer, T. Kreer, I. Drexler, T. Wölfel, and W. Herr The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays J. Immunol. Methods 259 2002 95
6. V. Cerundolo, J. Alexander, K. Anderson, C. Lamb, P. Cresswell, A. McMichael, F. Gotch, and A. Townsend Presentation of viral antigen controlled by a gene in the major histocompatibility complex Nature 345 1990 449
7. V. Cerundolo, A. Benham, V. Braud, S. Mukherjee, K. Gould, B. Macino, J. Neefjes, and A. Townsend The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells Eur. J. Immunol. 27 1997 336
8. P.M. Day, J.W. Yewdell, A. Porgador, R.N. Germain, and J.R. Bennink Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells Proc. Natl. Acad. Sci. U. S. A. 94 1997 8064
9. D.J. Diamond, J. York, J.Y. Sun, C.L. Wright, and S.J. Forman Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection Blood 90 1997 1751
10. A. Doerrschuck, A. Schmidt, E. Schnuerer, M. Glueckmann, C. Albrecht, C. Woelfel, V. Lennerz, A. Lifke, C. DiNatale, E. Ranieri, L. Gesualdo, C. Huber, M. Karas, T. Woelfel, and W. Herr CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA-class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression Blood 104 2004 2591
11. G. Fenteany, R.F. Standaert, W.S. Lane, S. Choi, E.J. Corey, and S.L. Schreiber Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin Science 268 1995 726
12. M. Gromme, F.G. Uytdehaag, H. Janssen, J. Calafat, R.S. van Binnendijk, M.J. Kenter, A. Tulp, D. Verwoerd, and J. Neefjes Recycling MHC class I molecules and endosomal peptide loading Proc. Natl. Acad. Sci. U. S. A. 96 1999 10326
13. W. Herr, B. Linn, N. Leister, E. Wandel, K.-H. Meyer zum Bueschenfelde, and T. Woelfel The use of computer-assisted video image analysis for the quantification of CD8-positive T lymphocytes producing TNF-alpha spots in response to peptide antigens J. Immunol. Methods 203 1997 141
14. W. Herr, E. Ranieri, A. Gambotto, L.S. Kierstead, A.A. Amoscato, L. Gesualdo, and W.J. Storkus Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood Proc. Natl. Acad. Sci. U. S. A. 96 1999 12033
15. W. Herr, E. Ranieri, W. Olson, H. Zarour, L. Gesualdo, and W.J. Storkus Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte response Blood 96 2000 1857
16. E. Jager, M. Ringhoffer, J. Karbach, M. Arand, F. Oesch, and A. Knuth Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo Int. J. Cancer 66 1996 470
17. M. Jondal, R. Schirmbeck, and J. Reimann MHC class I-restricted CTL responses to exogenous antigens Immunity 5 1996 295
18. H. Jonuleit, U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A.H. Enk Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions Eur. J. Immunol. 27 1997 3135
19. H.T. Khong, and N.P. Restifo Natural selection of tumor variants in the generation of "tumor escape" phenotypes Nat. Immunol. 3 2002 999
20. A.F. Kisselev, M. Garcia-Calvo, H.S. Overkleeft, E. Peterson, M.W. Pennington, H.L. Ploegh, N.A. Thornberry, and A.L. Goldberg The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites J. Biol. Chem. 278 2003 35869
21. P.M. Kloetzel, and F. Ossendorp Proteasome and peptidase function in MHC-class-I-mediated antigen presentation Curr. Opin. Immunol. 16 2004 76
22. J.O. Koopmann, G.J. Hammerling, and F. Momburg Generation, intracellular transport and loading of peptides associated with MHC class I molecules Curr. Opin. Immunol. 9 1997 80
23. C.J. Luckey, G.M. King, J.A. Marto, S. Venketeswaran, B.F. Maier, V.L. Crotzer, T.A. Colella, J. Shabanowitz, D.F. Hunt, and V.H. Engelhard Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol J. Immunol. 161 1998 112
24. T. Luft, M. Rizkalla, T.Y. Tai, Q. Chen, R.I. MacFarlan, I.D. Davis, E. Maraskovsky, and J. Cebon Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation J. Immunol. 167 2001 2529
25. L. Meng, R. Mohan, B.H. Kwok, M. Elofsson, N. Sin, and C.M. Crews Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity Proc. Natl. Acad. Sci. U. S. A. 96 1999 10403
26. S.K. Nair, D. Boczkowski, D. Snyder, and E. Gilboa Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines Eur. J. Immunol. 27 1997 589
27. F.O. Nestle, S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells Nat. Med. 4 1998 328
28. G. Niedermann, G. King, S. Butz, U. Birsner, R. Grimm, J. Shabanowitz, D.F. Hunt, and K. Eichmann The proteolytic fragments generated by vertebrate proteasomes: structural relationships to major histocompatibility complex class I binding peptides Proc. Natl. Acad. Sci. U. S. A. 93 1996 8572
29. H.W. Nijman, J.G. Houbiers, M.P. Vierboom, S.H. van der Burg, J.W. Drijfhout, J. D'Amaro, P. Kenemans, C.J. Melief, and W.M. Kast Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes Eur. J. Immunol. 23 1993 1215
30. L. Novellino, C. Castelli, and G. Parmiani A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol. Immunother. 54 2005 187
31. M. Orlowski, C. Cardozo, and C. Michaud Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids Biochemistry 32 1993 1563
32. M. Ostankovitch, A. Buzyn, D. Bonhomme, F. Connan, D. Bouscary, F. Heshmati, F. Dreyfus, J. Choppin, and J.G. Guillet Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts Blood 92 1998 19
33. V.J. Palombella, O.J. Rando, A.L. Goldberg, and T. Maniatis The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B Cell 78 1994 773
34. M.P. Protti, M.A. Imro, A.A. Manfredi, G. Consogno, S. Heltai, C. Arcelloni, M. Bellone, P. Dellabona, G. Casorati, and C. Rugarli Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro Cancer Res. 56 1996 1210
35. H.G. Rammensee Chemistry of peptides associated with MHC class I and class II molecules Curr. Opin. Immunol. 7 1995 85
36. I.V. Redchenko, and A.B. Rickinson Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells J. Virol. 73 1999 334
37. A.B. Rickinson, and D.J. Moss Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection Annu. Rev. Immunol. 15 1997 405
38. K.L. Rock, C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A.L. Goldberg Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules Cell 78 1994 761
39. R.D. Salter, D.N. Howell, and P. Cresswell Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids Immunogenetics 21 1985 235
40. G. Schuler, B. Schuler-Thurner, and R.M. Steinman The use of dendritic cells in cancer immunotherapy Curr. Opin. Immunol. 15 2003 138
41. K. Schwarz, R. de Giuli, G. Schmidtke, S. Kostka, M. van den Broek, K.B. Kim, C.M. Crews, R. Kraft, and M. Groettrup The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses J. Immunol. 164 2000 6147
42. J.C. Skipper, R.C. Hendrickson, P.H. Gulden, V. Brichard, A. Chen, Y. Shabanowitz, J. Wölfel, T. Slingluff, C.L.J. Boon, T. Hunt, and D.F. Engelhard An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins J. Exp. Med. 183 1996 527
43. W.J. Storkus, H.J. Zeh III, R.D. Salter, and M.T. Lotze Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution J. Immunother. 14 1993 94
44. L.C. Tan, N. Gudgeon, N.E. Annels, P. Hansasuta, C.A. O'Callaghan, S. Rowland-Jones, A.J. McMichael, A.B. Rickinson, and M.F. Callan A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers J. Immunol. 162 1999 1827
45. B. Thurner, I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, E.B. Brocker, R.M. Steinman, A. Enk, E. Kampgen, and G. Schuler Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J. Exp. Med. 190 1999 1669
46. E.B. Traenckner, S. Wilk, and P.A. Baeuerle A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B EMBO J. 13 1994 5433
47. M.J. Turk, J.D. Wolchok, J.A. Guevara-Patino, S.M. Goldberg, and A.N. Houghton Multiple pathways to tumor immunity and concomitant autoimmunity Immunol. Rev. 188 2002 122
48. A. Vinitsky, L.C. Anton, H.L. Snyder, M. Orlowski, J.R. Bennink, and J.W. Yewdell The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing? J. Immunol. 159 1997 554
49. T. Wölfel, M. Hauer, E. Klehmann, V. Brichard, B. Ackermann, A. Knuth, T. Boon, and K.H. Meyer zum Buschenfelde Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL) Int. J. Cancer. 55 1993 237
50. T. Wölfel, A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K.H. Meyer zum Buschenfelde, and T. Boon Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes Eur. J. Immunol. 24 1994 759
51. T. Wölfel, M. Hauer, J. Schneider, M. Serrano, C. Wölfel, E. Klehmann-Hieb, E. DePlaen, T. Hankeln, K.H. Meyer zum Buschenfelde, and D. Beach A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma Science 269 1995 1281
52. S. Yoshimura, J. Bondeson, F.M. Brennan, B.M. Foxwell, and M. Feldmann Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI Eur. J. Immunol. 31 2001 1883
53. D.M. Zaiss, S. Standera, P.M. Kloetzel, and A.J. Sijts PI31 is a modulator of proteasome formation and antigen processing Proc. Natl. Acad. Sci. U. S. A. 99 2002 14344
54. L. Zitvogel, J.I. Mayordomo, T. Tjandrawan, A.B. DeLeo, M.R. Clarke, M.T. Lotze, and W.J. Storkus Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines J. Exp. Med. 183 1996 87